Preoperative platelet count and survival prognosis in resected pancreatic ductal adenocarcinoma
Preoperative platelet count and survival prognosis in resected pancreatic ductal adenocarcinoma
复制标题
DOI：
10.1007/s00268-007-9423-6
复制
发表时间：
2008-06-01
影响因子：
2.6
通讯作者：
Fernandez-del Castillo, Carlos
中科院分区：
文献类型：
--
作者：
Dominguez, Ismael;Crippa, Stefano;Fernandez-del Castillo, Carlos
高血小板计数与多种肿瘤实体生存的不良影响有关。胰腺癌术前血小板计数的预后相关性尚未澄清。方法我们进行了回顾性分析，205例导管腺癌谁接受手术切除1990年至2003年。收集人口统计学、手术和临床病理学变量。结果205例患者中，56例（27.4%）为高血小板组，149例（72.6%）为低血小板组。总的中位生存期为17（2-178）个月。高血小板组的中位生存期为18（2-137）个月，低血小板组为15（2-178）个月（p = 0.7）。多因素分析显示，淋巴结转移、血管侵犯、切缘阳性、CA 19-9 > 200 U/ml均与胰腺导管腺癌的预后不良相关。使用5年实际生存数据证实，淋巴结转移，阳性切缘，血管浸润和CA 19-9是胰腺癌切除后生存率差的预测因子。
Background High platelet counts are associated with an adverse effect on survival in various neoplastic entities. The prognostic relevance of preoperative platelet count in pancreatic cancer has not been clarified.Methods We performed a retrospective review of 205 patients with ductal adenocarcinoma who underwent surgical resection between 1990 and 2003. Demographic, surgical, and clinicopathologic variables were collected. A cutoff of 300,000/mu l was used to define high platelet count.Results Of the 205 patients, 56 (27.4%) had a high platelet count, whereas 149 patients (72.6%) comprised the low platelet group. The overall median survival was 17 (2-178) months. The median survival of the high platelet group was 18 (2-137) months, and that of the low platelet group was 15 (2-178) months (p = 0.7). On multivariate analysis, lymph node metastasis, vascular invasion, positive margins, and CA 19-9 > 200 U/ml were all significantly associated with poor survival.Conclusions There is no evidence to support preoperative platelet count as either an adverse or favorable prognostic factor in pancreatic ductal adenocarcinoma. Use of 5-year actual survival data confirms that lymph node metastases, positive margins, vascular invasion, and CA 19-9 are predictors of poor survival in resected pancreatic cancer.